Lyell Immunopharma amends bylaws to modernize shareholder proposals and align with DGCL

Lyell Immunopharma, Inc.

Removed requirement for nominated directors to provide support information except on independence.
Limited disclosure of supporting stockholders to those financially backing the proposal.
Added disclosure requirements for certain extrinsic arrangements in director nomination notices.
Clarified that updates to proposals (e.g., new nominees) constitute new proposals subject to same procedures.
Conformed notice provisions and stockholder list requirements to DGCL Sections 232 and 219.

Key facts

Extracted from this filing and checked against the source text.

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

Lyell Immunopharma, Inc.: Amended and restated bylaws to modernize stockholder proposal procedures, clarify update rules, conform notice provisions to DGCL Section 232, simplify voting standards, and conform stockholder list requirements to DGCL Section 219 (effective 2025-12-03).

Change: bylaw amendment
Effective: 2025-12-03

Exact text from the filing

On December 3, 2025, the Board of Directors (the “Board”) of Lyell Immunopharma, Inc. (the “Company”) amended and restated the Company’s Amended and Restated Bylaws (the “Amended Bylaws”), effective immediately.

View on SEC.gov

83 governance changes filed in the last 30 days. Browse all governance changes →

Lyell Immunopharma, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-25-309621

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.